The FDA reportedly is planning to authorize the Pfizer-BioNTech (NYSE:PFE/NSDQ:BNTX) COVID-19 vaccine booster for all adults in the coming days. FDA could make an announcement on the subject as soon as tomorrow, according to The New York Times.
CDC’s Advisory Committee on Immunization Practices (ACIP) plans on discussing the Pfizer-BioNTech booster data on November 19.
A growing number of U.S. states authorized the vaccine boosters for all adults, including California, Colorado, New Mexico, Kansas, Vermont, Kentucky and Maine.
In September, Pfizer asked federal officials to authorize the vaccine booster for all adults. Instead, it received limited authorization for high-risk groups.
To bolster its application for vaccine boosters for all adults, Pfizer included clinical trial data involving 10,000 participants who received a booster dose.
The news comes as U.S. COVID-19 cases have risen 18% in the past 14 days after having fallen steadily in most U.S. states since mid-September.
Yesterday, Pfizer submitted paperwork to the FDA requesting authorization for Paxlovid, the company’s COVID-19 antiviral cocktail.
Moderna (NSDQ:MRNA) is also seeking authorization for its COVID-19 booster for all adults.
According to the CDC, some 30.7 million Americans have received their booster shots to date.
Filed Under: clinical trials, Drug Discovery, Immunology